Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Nat Immunol. 2014 May;15(5):415–422. doi: 10.1038/ni.2872

Figure 4. Therapeutic Strategies to Mitigate Cell Intrinsic Activation of the ISD Pathway.

Figure 4

Failure to metabolize reverse transcribed products causes inappropriate activation of the DNA sensing pathway, chronic type I IFN production, and autoimmune disease. Disease intervention strategies include blockade of type I IFNs, preventing signaling through the ISD pathway through TBK1 specific inhibitors, and elimination of reverse transcribed products through the use of reverse transcriptase inhibitors (RTIs).